EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)
January 04, 2024 08:00 ET
|
EG 427
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In a non-clinical pharmacology study in an OAB model,...
EG 427 announces final Series A closing, achieving €18 million in total funds raised
July 13, 2023 02:00 ET
|
EG 427
Paris, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. EG 427 raised an...